AIMS/HYPOTHESIS: Sphingolipid synthesis is typically initiated by the conjugation of L-serine and palmitoyl-CoA, a reaction catalysed by serine palmitoyltransferase (SPT). SPT can also metabolise other acyl-CoAs (C(12) to C(18)) and other amino acids such as L-alanine and glycine, giving rise to a spectrum of atypical sphingolipids. Here, we aimed to identify changes in plasma levels of these atypical sphingolipids to explore their potential as biomarkers in the metabolic syndrome and diabetes. METHODS: We compared the plasma profiles of ten sphingoid bases in healthy individuals with those of patients with the metabolic syndrome but not diabetes, and diabetic patients (n = 25 per group). The results were verified in a streptozotocin (STZ) rat model. Univariate and multivariate statistical analyses were used. RESULTS: Deoxysphingolipids (dSLs) were significantly elevated (p = 5 × 10⁻⁶) in patients with the metabolic syndrome (0.11 ± 0.04 μmol/l) compared with controls (0.06 ± 0.02 μmol/l) but did not differ between the metabolic syndrome and diabetes groups. Levels of C(16)-sphingosine-based sphingolipids were significantly lowered in diabetic patients but not in patients with the metabolic syndrome but without diabetes (p = 0.008). Significantly elevated dSL levels were also found in the plasma and liver of STZ rats. A principal component analysis revealed a similar or even closer association of dSLs with diabetes and the metabolic syndrome in comparison with the established biomarkers. CONCLUSIONS/ INTERPRETATION: We showed that dSLs are significantly elevated in patients with type 2 diabetes mellitus and non-diabetic metabolic syndrome compared with healthy controls. They may, therefore, be useful novel biomarkers to improve risk prediction and therapy monitoring in these patients.
AIMS/HYPOTHESIS: Sphingolipid synthesis is typically initiated by the conjugation of L-serine and palmitoyl-CoA, a reaction catalysed by serine palmitoyltransferase (SPT). SPT can also metabolise other acyl-CoAs (C(12) to C(18)) and other amino acids such as L-alanine and glycine, giving rise to a spectrum of atypical sphingolipids. Here, we aimed to identify changes in plasma levels of these atypical sphingolipids to explore their potential as biomarkers in the metabolic syndrome and diabetes. METHODS: We compared the plasma profiles of ten sphingoid bases in healthy individuals with those of patients with the metabolic syndrome but not diabetes, and diabeticpatients (n = 25 per group). The results were verified in a streptozotocin (STZ) rat model. Univariate and multivariate statistical analyses were used. RESULTS: Deoxysphingolipids (dSLs) were significantly elevated (p = 5 × 10⁻⁶) in patients with the metabolic syndrome (0.11 ± 0.04 μmol/l) compared with controls (0.06 ± 0.02 μmol/l) but did not differ between the metabolic syndrome and diabetes groups. Levels of C(16)-sphingosine-based sphingolipids were significantly lowered in diabeticpatients but not in patients with the metabolic syndrome but without diabetes (p = 0.008). Significantly elevated dSL levels were also found in the plasma and liver of STZrats. A principal component analysis revealed a similar or even closer association of dSLs with diabetes and the metabolic syndrome in comparison with the established biomarkers. CONCLUSIONS/ INTERPRETATION: We showed that dSLs are significantly elevated in patients with type 2 diabetes mellitus and non-diabetic metabolic syndrome compared with healthy controls. They may, therefore, be useful novel biomarkers to improve risk prediction and therapy monitoring in these patients.
Authors: H U Humpf; E M Schmelz; F I Meredith; H Vesper; T R Vales; E Wang; D S Menaldino; D C Liotta; A H Merrill Journal: J Biol Chem Date: 1998-07-24 Impact factor: 5.157
Authors: Timothy D Wiggin; Kelli A Sullivan; Rodica Pop-Busui; Antonino Amato; Anders A F Sima; Eva L Feldman Journal: Diabetes Date: 2009-05-01 Impact factor: 9.461
Authors: Regula Steiner; Essa M Saied; Alaa Othman; Christoph Arenz; Alan T Maccarone; Berwyck L J Poad; Stephen J Blanksby; Arnold von Eckardstein; Thorsten Hornemann Journal: J Lipid Res Date: 2016-05-10 Impact factor: 5.922
Authors: Andrew J Clifford; Kehui Chen; Laura McWade; Gonzalo Rincon; Seung-Hyun Kim; Dirk M Holstege; Janel E Owens; Bitao Liu; Hans-Georg Müller; Juan F Medrano; James G Fadel; Alanna J Moshfegh; David J Baer; Janet A Novotny Journal: J Nutr Date: 2012-07-25 Impact factor: 4.798
Authors: Irina Alecu; Andrea Tedeschi; Natascha Behler; Klaus Wunderling; Christian Lamberz; Mario A R Lauterbach; Anne Gaebler; Daniela Ernst; Paul P Van Veldhoven; Ashraf Al-Amoudi; Eicke Latz; Alaa Othman; Lars Kuerschner; Thorsten Hornemann; Frank Bradke; Christoph Thiele; Anke Penno Journal: J Lipid Res Date: 2016-11-23 Impact factor: 5.922
Authors: Museer A Lone; Andreas J Hülsmeier; Essa M Saied; Gergely Karsai; Christoph Arenz; Arnold von Eckardstein; Thorsten Hornemann Journal: Proc Natl Acad Sci U S A Date: 2020-06-23 Impact factor: 11.205
Authors: Saranya Suriyanarayanan; Mari Auranen; Jussi Toppila; Anders Paetau; Maria Shcherbii; Eino Palin; Yu Wei; Tarja Lohioja; Beate Schlotter-Weigel; Ulrike Schön; Angela Abicht; Bernd Rautenstrauss; Henna Tyynismaa; Maggie C Walter; Thorsten Hornemann; Emil Ylikallio Journal: Neuromolecular Med Date: 2015-11-16 Impact factor: 3.843